Clinical trials: Pediatric Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention Deficit Disorder With Hyperactivity
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
- Trial name
- NCT00151970
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 128 people
- Sponsor
- Noven Therapeutics
ADHD
Impact of Parental Emotion Regulation on the Treatment of ADHD
Aim: To examine if parental emotion regulation (ER) moderates the response to parent training interventions. H1: Reduced parental ER capacity will predict diminished efficacy for behavioral parent training to improve negative…
- Trial name
- PERS (NCT05299814)
- Testing
- Behavioral Parenting Intervention
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Milton S. Hershey Medical Center
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
ADHD
EEG Biomarkers for ADHD Stimulant Treatment
Pediatric attention deficit hyperactivity disorder (ADHD) affects up to 10% of children in the U.S. and more than 90% are prescribed stimulant medications according to clinical guidelines.
- Trial name
- NCT07650643
- Testing
- methylphenidate HCl, Mixed amphetamine salts extended release
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Boston Children's Hospital
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
There has been an increased interest in the association between ADHD and sleep disorders over the past years. A high incidence of sleep disturbance, ranging from 10% to 70%, has been identified in ADHD children regardless of…
- Trial name
- Zolkids (NCT00318448)
- Testing
- Zolpidem (SL800750)
- Where
- 2 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Sanofi
Attention Deficit Disorder, Attention Deficit Disorder (ADD)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the…
- Conditions
- Attention Deficit Disorder, Attention Deficit Disorder (ADD), Attention Deficit Disorder with Hyperactivity, ADHD
- Trial name
- NOVA (NCT06797570)
- Testing
- Communication Strategy for Side Effect Counseling in ADHD Treatment
- Volunteers
- 130 people
- Sponsor
- St. Antonius Hospital
Disruptive Behavior
Clinical and Social Trajectory of Children and Adolescents With Disruptive Behavior
Conduct disorders are defined as "repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate norms are violated".
- Trial name
- TRAJECTORY (NCT02828969)
- Testing
- Phone call or physical consultation
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Implementation Research, Depressive Disorder
Pediatric Behavioral Health Integrated Care: Indiana Statewide Strategic Plan to Address the Growing Mental Health Crisis
This research is designed to analyze the implementation and fidelity of Pediatric Integrated Behavioral Health (PEDS-IBH). PEDS-IBH is a multifaceted project designed to address the pediatric mental health crisis by providing…
- Conditions
- Implementation Research, Depressive Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Conduct Disorders in Children
- Trial name
- PEDS-IBH (NCT07216638)
- Where
- United States
- Volunteers
- 575 people
- Sponsor
- Indiana University
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder
Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)
Background: Irritability is an elevated proneness to anger. Children with irritability have difficulty tolerating frustration. They get angry and have temper outbursts more easily than their others their age.
- Conditions
- Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
- Trial name
- NCT05357495
- Testing
- Affective Posner fMRI frustration induction task
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Childhood Depression, Childhood Anxiety
Integrative Coping Group for Children
The purpose of this study is to examine whether an integrative group-based intervention will help children experiencing psychological and physical distress.
- Conditions
- Childhood Depression, Childhood Anxiety, Pediatric Pain, Migraines
- Trial name
- ToPSY (NCT01813669)
- Testing
- Integrative Coping Group
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Duke University
Attention-Deficit Hyperactivity Disorder(ADHD)
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.
- Trial name
- NCT07087327
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Traumatic Brain Injury, TBI
Methylphenidate for Attention Problems After Pediatric TBI
Traumatic Brain Injury (TBI) - methylphenidate treatment
- Conditions
- Traumatic Brain Injury, TBI, ADHD
- Trial name
- NCT01933217
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in pediatric subjects with ADHD.
- Trial name
- NCT04398225
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit Hyperactivity Disorder
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.
- Trial name
- NCT01886469
- Testing
- HLD100-B, HLD100-C, HLD100-E
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Mood Disorder
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability…
- Trial name
- NCT00025935
- Testing
- Lithium
- Where
- United States
- Volunteers
- 2,350 people
- Sponsor
- National Institute of Mental Health (NIMH)
Neurodevelopmental Disorders, Pediatric Sleep Apnea
Ambulatory Polysomnography in Neurodiverse Children: Feasibility, Quality, and Satisfaction
Laboratory polysomnography is the gold standard for objective sleep measurement. With hospital waiting times becoming increasingly long, outpatient polysomnography seems a good solution.
- Conditions
- Neurodevelopmental Disorders, Pediatric Sleep Apnea, Periodic Leg Movements, Excessive, Sleep-Related, Polysomnography
- Trial name
- NCT06966973
- Testing
- Polysomnograpy
- Where
- France
- Volunteers
- 563 people, healthy volunteers welcome
- Sponsor
- UPNOS
Pediatric Onset Multiple Sclerosis, ADHD Predominantly Inattentive Type
Cognitive Impairment in Pediatric Onset Multiple Sclerosis
Computer-assisted rehabilitation of attention deficits in pediatric Multiple Sclerosis and ADHD patients recruited during the study "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of…
- Trial name
- NCT03190902
- Testing
- Attention Processing Training program (APT), nonspecific computer training (n-ST)
- Volunteers
- 36 people
- Sponsor
- Pietro Iaffaldano
Attention Deficit Hyperactivity Disorder
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
This study is a single arm, open-label, pilot study to assess midline frontal theta (MFT) power as measured by stimulus-locked electroencephalogram (EEG) before and after treatment with AKL-T01 for improving attention in…
- Trial name
- NCT03844269
- Testing
- AKL-T01
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Akili Interactive Labs, Inc.